Ruxolitinib for vitiligo

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 25 Jul 2024: Trial started, NCT07725432
  2. 24 Jul 2026: Trial registered, NCT07725432

The trials

NCT07725432: Topical Ruxolitinib Evaluation in Immune-related Vitiligo-like Depigmentation

State
Under way
Phase
Phase 2
People
34 planned
Started
25 Jul 2024
Primary completion
7 Jul 2026
Arms
Topical ruxolitinib
Results
None posted
  1. 25 Jul 2024: Trial started
  2. 24 Jul 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Post-transplant Ruxolitinib, Ruxolitinib 5 MG.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.